Loading…
As of 9 Nov 2026: Bliss GVS Pharma ₹654.75 (m-cap ₹6,947 Cr, P/E 43.0) vs Innova Captab ₹1,068.90 (m-cap ₹6,118 Cr, P/E 39.9). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | Bliss GVS Pharma | Innova Captab |
|---|---|---|
| Share price | ₹654.75 | ₹1,068.90 |
| Day change | +4.89% | +0.15% |
| Market cap | ₹6,947 Cr | ₹6,118 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | 43.0 | 39.9 |
| P/BPrice ÷ book value per share. | 5.8 | 5.6 |
| ROEReturn on equity. | 11.8% | 13.7% |
| ROCEReturn on capital employed. | 17.0% | 15.0% |
| Sales growth (3Y CAGR) | — | — |
| Profit growth (3Y CAGR) | — | — |
| Debt to equity | 0.02 | 0.32 |
| Dividend yield | 0.23% | 0.19% |
| 1-year price return | +411.9% | +39.3% |
| Promoter holding | — | — |
| Industry | Pharmaceuticals | Pharmaceuticals |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Bliss GVS Pharma Ltd is larger, with a market cap of ₹6,947 Cr against ₹6,118 Cr for Innova Captab Ltd as of 9 Nov 2026 — about 1.1 times the size.
Innova Captab Ltd trades at a P/E of 39.9 against 43.0 for Bliss GVS Pharma Ltd as of 9 Nov 2026. A lower P/E alone does not make a share cheaper in value terms: growth, return on capital and debt differ between companies.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours (delayed by up to 15 minutes) and ratios update when the companies report results. Each number is the same one shown on the two stock pages.